LifeStent™ Vascular Stent System
Self-expanding nitinol stent for the SFA and popliteal artery · Peripheral Vascular

LifeStent™ Vascular Stent System

The LifeStent™ Vascular Stent System is part of the Bard portfolio supplied by BD. BD describes it as a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and popliteal artery. According to BD, the stent has a unique helical design engineered for bending, compression and torsion with dynamic vessel conformability, intended to withstand the mechanical demands of the femoropopliteal segment. BD reports substantial clinical experience with the platform, stating that the LifeStent™ Vascular Stent Systems in varying sizes have been studied in more than ten clinical trials in the United States and globally, with results that BD describes as showing sustained effectiveness up to three years and treatment superiority over balloon angioplasty. BD also states that it is the only commercially available bare metal stent FDA-approved for the superficial femoral and full popliteal arteries, and cites the longest lesion length indication among its features, with lesions up to 240 mm in length. For interventional and vascular surgery teams in Azerbaijan, the relevant interest is a well-studied nitinol stent for the femoropopliteal segment. Azmed Devices provides manufacturer documentation, registration status, tender support and supply coordination for BD peripheral vascular products. Detailed specifications and available configurations are available on request.

Sizes & Specifications

Specifications
Available on request

Manufacturer: C. R. Bard, Inc. (a BD company) · Reference source: bd.com

Product Features

Design characteristics as published by Bard.

Helical design

BD describes a unique helical design engineered for bending, compression and torsion with dynamic vessel conformability.

SFA and popliteal indication

BD states it is FDA-approved for the superficial femoral artery and full popliteal artery.

Long lesion coverage

BD cites the longest lesion length indication, treating lesions up to 240 mm in length.

Sustained effectiveness

BD states the stent has shown sustained effectiveness up to three years and treatment superiority over balloon angioplasty.

Extensive clinical study

BD reports the systems have been studied in more than ten clinical trials in the United States and globally.

Documentation

Official IFU, diameter and length matrix and full specifications are available on request through Azmed Devices.

Product Identification & Specifications

Reference identifiers for procurement, registration and tender documentation.

ManufacturerC. R. Bard, Inc. (a BD company)
BrandBard
Product FamilyPeripheral Vascular
Country AvailabilityAzerbaijan

Clinical Applications

The LifeStent™ Vascular Stent System is a self-expanding nitinol stent for the sfa and popliteal artery in the Peripheral Vascular family from C. R. Bard, Inc. (a BD company), used by interventional specialists in procedures where a self-expanding nitinol stent for the sfa and popliteal artery of this class is indicated.

For the complete indications for use, contraindications and instructions for use (IFU), request the official Bard documentation through our clinical team. Azmed Devices supplies the LifeStent™ Vascular Stent System to hospitals and clinics across Azerbaijan.

Downloads & Documentation

Instructions for use (IFU), technical datasheets and clinical literature for the LifeStent™ Vascular Stent System are available on request from our clinical team.

Request Documentation

Frequently Asked Questions

Which vessels is the LifeStent Vascular Stent indicated for?
BD describes it as a peripheral stent intended to improve luminal diameter in the native superficial femoral artery (SFA) and popliteal artery, and states it is FDA-approved for the SFA and full popliteal artery.
What clinical evidence does BD cite?
BD states the LifeStent™ systems have been studied in more than ten clinical trials in the US and globally, with sustained effectiveness up to three years and treatment superiority over balloon angioplasty.
How can our hospital order LifeStent Vascular Stent System in Azerbaijan?
Contact Azmed Devices at info@azmeddevices.com. We provide manufacturer documentation, registration status and tender support, and coordinate supply for BD technologies.

Related in Peripheral Vascular